Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cells. Researchers can modify a person s own T cells, or immune cells, to target B7-H3. When these modified T cells are returned to the body-a treatment called B7-H3 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells. Objective: To test B7-H3 CAR T cell therapy in people with SCLC or EPNEC. Eligibility: People aged 18 years and older with SCLC or EPNEC that either did not respond or returned after treatment. Design: Participants will be screened. They will have blood tests and tests of their heart function. They will have imaging scans. Participants will undergo apheresis: Blood will be taken from the body through a needle. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different needle. The collected T cells will be altered to make them attack cells with B7-H3. Participants will be in the hospital for at least 15 days. They will receive chemotherapy drugs to prepare their body for the treatment. These drugs will be given through a tube attached to a needle inserted into a vein. The modified T cells will be infused through a vein. Participants will remain in the hospital until they are well enough to go home. Follow-up visits will continue for 15 years....
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rak płuca lub nowotwór neuroendokrynny, który wrócił po leczeniu lub nie reaguje na pierwsze leczenie
- •Stan ogólny pacjenta pozwalający na uczestnictwo w badaniu
- •Nasycenie krwi tlenem co najmniej 90 procent
- •Prawidłowa funkcja wątroby (wskaźniki transaminaz poniżej limitów)
- •Prawidłowa funkcja nerek (kreatynina poniżej limitu)
- •Wystarczająca liczba białych krwinek i płytek krwi
- •Prawidłowa funkcja serca (frakcja wyrzutowa co najmniej 45 procent)
✗ Disqualifies
- •Nie spełnia wymaganych wartości laboratoryjnych dotyczących wątroby, nerek, białych krwinek i płytek
- •Chemioterapia podana mniej niż 14 dni przed procedurą
- •Terapia biologiczna lub celowana podana mniej niż 7 dni przed procedurą
- •Przeciwciała monoklonalne podane mniej niż 3 tygodnie lub 5 półperiod przed procedurą
- •Uszkodzenie serca lub zaburzenia rytmu serca
- •Infekcja aktywna lub immunosupresja
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Stephanie N Hicks
Nicholas P Tschernia, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.